AGENUS INC (AGEN)       2.79  -0.18 (-6.06%)

2.79  -0.18 (-6.06%)

US00847G7051 - Common Stock - After market: 2.8 +0.01 (+0.36%)


Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to AGEN. AGEN was compared to 635 industry peers in the Biotechnology industry. AGEN has a bad profitability rating. Also its financial health evaluation is rather negative. AGEN is valued expensive and it does not seem to be growing.




Profitability

Profitability Rating

1

AGEN has a Return On Assets of -50.00%. This is comparable to the industry average of -44.83%.
AGEN's Profit Margin of -238.59% is in line with the rest of the industry. The industry average Profit Margin is -464.10%.

AGEN has negative profitability rations, so we won't be analyzing them here.
The Piotroski-F score of AGEN is 2.00. This is a very weak score and indicates problems in health and profitability for AGEN.
VS Industry

ROA (-50%) VS Industry: 44% outperformed.

-3,944.82
115.38

Profit Margin (-238.59%) VS Industry: 59% outperformed.

-1,173,705.71
34,743.00

Valuation

Valuation Rating

0

The Price/Earnings Ratio is negative for AGEN. In the last year negative earnings were reported.

Also next year AGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Growth

Growth Rating

2

Measured over the past 5 years, AGEN shows a very strong growth in Revenue. The Revenue has been growing by 67.24% on average per year.
AGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -440.00%.
Based on estimates for the next 5 years, AGEN will show a very negative growth in Earnings Per Share. The EPS will decrease by -27.72% on average per year.

The Revenue for AGEN has decreased by -70.68% in the past year. This is quite bad
The Revenue is expected to decrease by -13.70% on average over the next 5 years. This is quite bad
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -440% -255.79% -77% -40.83% -27.72%
Revenue67.24% 100.29% -70.68% -69.99% -45.31% -27.57% -13.7%

Health

Health Rating

1

AGEN has a Current Ratio of 1.45. This is a normal value and indicates that AGEN is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.45 indicates that AGEN should not have too much problems paying its short term obligations.
The Debt to Equity ratio of AGEN is in line with the industry averages.
Compared to an average industry Current Ratio of 6.11, AGEN is worse placed to pay its short term obligations than its industry peers. 90% of its industry peers have a better Current Ratio.

Compared to an average industry Quick Ratio of 6.02, AGEN is worse placed to pay its short term obligations than its industry peers. 89% of its industry peers have a better Quick Ratio.
AGEN has an Altman-Z score of -5.09. This is a bad value and indicates that AGEN is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.65, AGEN is in worse financial health than its industry peers.
AGEN has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for AGEN.
VS Industry

Debt/Equity (0) VS Industry: 41% outperformed.

15.37
0.00

Quick Ratio (1.45) VS Industry: 11% outperformed.

0.02
84.53

Current Ratio (1.45) VS Industry: 10% outperformed.

0.02
85.09

Altman-Z (-5.09) VS Industry: 28% outperformed.

-1,822.12
441.73

Dividend

Dividend Rating

0

AGEN does not give a dividend.

AGEN Daily chart

AGENUS INC2.79

NASDAQ:AGEN (12/5/2022, 7:18:23 PM)-0.18 (-6.06%)

After market: 2.8 +0.01 (+0.36%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-08 2022-11-08/bmo Earnings (Next) 02-27 2023-02-27
Ins Owners 0.46% Inst Owners 53.83%
Market Cap 850.43M Analysts 86
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 9.46 P/B N/A
EV/EBITDA -4.02
Dividend
Dividend Yield N/A Dividend Growth N/A
DP 0% Ex-Date N/A
Growth
EPS 1Y -440% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -127.54%
EPS Next Y -255.79% EPS Next 2Y -77%
EPS Next 3Y -40.83% EPS Next 5Y -27.72%
Revenue growth 1Y -70.68% Revenue growth 3Y 100.29%
Revenue growth 5Y 67.24% Revenue growth Q2Q -91%
Revenue Next Year -69.99% Revenue Next 2Y -45.31%
Revenue Next 3Y -27.57% Revenue Next 5Y -13.7%
Health
Current Ratio 1.45 Quick Ratio 1.45
Altman-Z -5.09 F-Score 2
Debt/Equity 0 WACC 9%
ROIC/WACC N/A
Profitability
ROA -50% ROE N/A
ROICexgc N/A ROIC N/A
PM -238.59% OM -198.77%
Asset Turnover 0.21

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA